Christian Labenz, Yvonne Huber, Maurice Michel, Michael Nagel, Peter R. Galle, Karel Kostev, Jörn M. Schattenberg – 22 June 2020 – Nonalcoholic fatty liver disease (NAFLD), depression, and anxiety disorders are frequent diseases, and data on mutual influence are inconsistent. The aim of this study was to explore the incidence of depression and anxiety in a large primary care cohort in Germany and to study the impact of NAFLD over a 10‐year time frame.

Haixia Xu, Yan Tian, Dongmei Tang, Sailan Zou, Geng Liu, Jiulin Song, Guixiang Zhang, Xiao Du, Wei Huang, Bin He, Weiqiang Lin, Liang Jin, Wendong Huang, Jiayin Yang, Xianghui Fu – 22 June 2020

Puru Rattan, Carlos D. Minacapelli, Vinod Rustgi – 21 June 2020 – The human microbiome is a vast and complex system encompassing all of the microbes and their genes that occupy the environmentally exposed surfaces of the human body. The gut microbiota and its associated microbiome play an integral role in mammalian metabolism and immune tolerance as well as in immunocompetence. Disruptions in the human gut microbiome are associated with a cycle of hepatocyte injury and regeneration characteristic of chronic liver disease.

Therese Bittermann, Kristen Dwinnells, Sakshum Chadha, Michael S. Wolf, Kim M. Olthoff, Marina Serper – 21 June 2020 – The effect of low health literacy (HL) on outcomes in end‐stage liver disease (ESLD) is largely unknown. The association of low HL on clinical outcomes was investigated in a prospective cohort of outpatients with ESLD undergoing liver transplantation (LT) evaluation. From 2014 to 2017, 276 patients underwent LT evaluation with assessments of liver disease severity, medical and psychosocial comorbidities, physical frailty, and malnutrition.

Vijay Waman Dhakre, Preet Shah, Sanjay S. Nagral, Aabha Nagral – 20 June 2020

Masahito Nakano, Ryoko Kuromatsu, Takashi Niizeki, Shusuke Okamura, Hideki Iwamoto, Shigeo Shimose, Tomotake Shirono, Yu Noda, Naoki Kamachi, Hironori Koga, Takuji Torimura, The Kurume Liver Cancer Study Group of Japan – 20 June 2020 – Sorafenib and lenvatinib, as molecular‐targeted agents, constitute effective primary treatment options for advanced hepatocellular carcinoma (HCC). However, the choice of optimal primary treatment agent remains controversial.

David D. Lee, Scott J. Cotler – 20 June 2020

Toru Ikegami, Kenei Furukawa, Yoshihiro Shirai, Jyungo Yasuda, Takeshi Gocho – 19 June 2020

Nachiket Vartak, Georgia Guenther, Florian Joly, Amruta Damle‐Vartak, Gudrun Wibbelt, Jörns Fickel, Simone Jörs, Brigitte Begher‐Tibbe, Adrian Friebel, Kasimir Wansing, Ahmed Ghallab, Marie Rosselin, Noemie Boissier, Irene Vignon‐Clementel, Christian Hedberg, Fabian Geisler, Heribert Hofer, Peter Jansen, Stefan Hoehme, Dirk Drasdo, Jan G. Hengstler – 19 June 2020

Thomas G. Cotter, Jennifer Wang, Thoetchai Peeraphatdit, Burhaneddin Sandıkçı, Fares Ayoub, Gene Kim, Helen Te, Valluvan Jeevanandam, Diego Sabato, Michael Charlton – 19 June 2020